Glycopyrronium EQL Pharma contains glycopyrronium bromide and is a so-called anticholinergic which is used in hospital care, among other things, to counteract salivary secretion during operations in the mouth, throat or trachea.
Glycopyrronium EQL Pharma will be EQL's third approved inpatient care product and will be sold through public tenderering in all four Nordic countries. The market is growing and worth approximately SEK 30 million annually with three active competitors. The launch is dependent on the result of tenders for procurements but can take place at the earliest in the fourth quarter (January-March) of EQL's financial year.
For further information, please contact:
Christer Fåhraeus
CEO,
Phone: +46 (0) 705 - 60 90 00
E-mail: christer.fahraeus@eqlpharma.com
Website: www.eqlpharma.com
https://news.cision.com/eql-pharma/r/eql-pharma-get-glycopyrronium-eql-pharma-approved,c3561188
https://mb.cision.com/Main/11664/3561188/1575272.pdf
(c) 2022 Cision. All rights reserved., source